Remote Electrical Neuromodulation for Migraines

This policy covers remote electrical neuromodulation (REN) using the FDA‑cleared Nerivio device for preventive treatment of migraine. Coverage is for patients with ICHD‑3–diagnosed migraine (adults, and select pediatric patients 8–17 when criteria met) who have 6–24 headache days per 28‑day period for each of the prior 3 months and who have failed, are intolerant of, or have contraindications to ≥2 guideline preventive medications; continuation requires documented benefit after an 8–12 week trial, REN is contraindicated with uncontrolled epilepsy or active implantable electronic devices, and acute REN is considered investigational and not covered.

"Remote electrical neuromodulation (REN, e."

Sign up to see full coverage criteria, indications, and limitations.